Panel Discussion: Strengthening IPO Readiness to Reduce Liability Exposure & Support Defensible Board Decision‑Making

3:15 pm - Wednesday 5th August 2026

  •  Build disclosure discipline early by aligning scientific claims, press releases, BD decks, and public statements to withstand S‑1 scrutiny
  • Reduce litigation and enforcement risk through structured risk‑factor design and clear escalation controls
  • Strengthen board decision‑making with disciplined go/no‑go criteria, documentation standards, and scenario pathways
  • Prepare for life as a public company by aligning IPO readiness with post‑IPO ongoing public company obligations, capital markets strategy, contingency planning, and dual‑track financing scenarios

Speakers:

Chief Legal Officer
Caribou Biosciences, Inc.
Chief Legal Officer
Sionna Therapeutics
General Counsel and Corporate Secretary
Connect Biopharma
CLO
Immuneering Corp.
Chief Legal Officer, Head of Quality & Corporate Secretary
Boundless Bio
Formerly Chief Legal Officer
Lexeo Therapeutics